| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Animal Model |
From the Department of Molecular Pharmacology and The Albert Einstein Cancer Center,* Albert Einstein College of Medicine; the Department of Pathology, Albert Einstein College of Medicine and Montefiore Medical Center; the Divisions of Cardiology and Infectious Disease, Department of Medicine, Albert Einstein College of Medicine and The Montefiore Medical Center; the Department of Pathology, Albert Einstein College of Medicine, Bronx, New York
Caveolin-1 is the principal protein component of caveolae membrane domains, which are located at the cell surface in most cell types. Evidence has accumulated suggesting that caveolin-1 may function as a suppressor of cell transformation in cultured cells. The human CAV-1 gene is located at a putative tumor suppressor locus (7q31.1/D7S522) and a known fragile site (FRA7G) that is deleted in a variety of epithelial-derived tumors. Mechanistically, caveolin-1 is known to function as a negative regulator of the Ras-p42/44 MAP kinase cascade and as a transcriptional repressor of cyclin D1, possibly explaining its transformation suppressor activity in cultured cells. However, it remains unknown whether caveolin-1functions as a tumor suppressor gene in vivo. Here, we examine the tumor suppressor function of caveolin-1 using Cav-1 (-/-) null mice as a model system. Cav-1 null mice and their wild-type counterparts were subjected to carcinogen-induced skin tumorigenesis, using 7,12-dimethylbenzanthracene (DMBA). Mice were monitored weekly for the development of tumors. We demonstrate that Cav-1 null mice are dramatically more susceptible to carcinogen-induced tumorigenesis, as they develop skin tumors at an increased rate. After 16 weeks of DMBA-treatment, Cav-1 null mice showed a 10-fold increase in tumor incidence, a 15-fold increase in tumor number per mouse (multiplicity), and a 35-fold increase in tumor area per mouse, as compared with wild-type littermate mice. Moreover, before the development of tumors, DMBA-treatment induced severe epidermal hyperplasia in Cav-1 null mice. Both the basal cell layer and the suprabasal cell layers were expanded in treated Cav-1 null mice, as evidenced by immunostaining with cell-type specific differentiation markers (keratin-10 and keratin-14). In addition, cyclin D1 and phospho-ERK1/2 levels were up-regulated during epidermal hyperplasia, suggesting a possible mechanism for the increased susceptibility of Cav-1 null mice to tumorigenesis. However, the skin of untreated Cav-1 null mice appeared normal, without any evidence of epidermal hyperplasia, despite the fact that Cav-1 null keratinocytes failed to express caveolin-1 and showed a complete ablation of caveolae formation. Thus, Cav-1 null mice require an appropriate oncogenic stimulus, such as DMBA treatment, to reveal their increased susceptibility toward epidermal hyperplasia and skin tumor formation. Our results provide the first genetic evidence that caveolin-1 indeed functions as a tumor suppressor gene in vivo.
This article has been cited by other articles:
 |
|
 |
|
  M. Gadjeva, C. Paradis-Bleau, G. P. Priebe, R. Fichorova, and G. B. Pier Caveolin-1 Modifies the Immunity to Pseudomonas aeruginosa J. Immunol., January 1, 2010; 184(1): 296 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Sloan, H. A. Marquez, J. Li, Y. Cao, A. Hinds, C. J. O'Hara, S. Kathuria, M. I. Ramirez, M. C. Williams, and H. Kathuria Increased PEA3/E1AF and decreased Net/Elk-3, both ETS proteins, characterize human NSCLC progression and regulate caveolin-1 transcription in Calu-1 and NCI-H23 NSCLC cell lines Carcinogenesis, August 1, 2009; 30(8): 1433 - 1442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Sotgia, F. Del Galdo, M. C. Casimiro, G. Bonuccelli, I. Mercier, D. Whitaker-Menezes, K. M. Daumer, J. Zhou, C. Wang, S. Katiyar, et al. Caveolin-1-/- Null Mammary Stromal Fibroblasts Share Characteristics with Human Breast Cancer-Associated Fibroblasts Am. J. Pathol., March 1, 2009; 174(3): 746 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Bailey and J. Liu Caveolin-1 Up-regulation during Epithelial to Mesenchymal Transition Is Mediated by Focal Adhesion Kinase J. Biol. Chem., May 16, 2008; 283(20): 13714 - 13724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Langlois, K. N. Cowan, Q. Shao, B. J. Cowan, and D. W. Laird Caveolin-1 and -2 Interact with Connexin43 and Regulate Gap Junctional Intercellular Communication in Keratinocytes Mol. Biol. Cell, March 1, 2008; 19(3): 912 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Zemans and G. P. Downey Role of caveolin-1 in regulation of inflammation: different strokes for different folks Am J Physiol Lung Cell Mol Physiol, February 1, 2008; 294(2): L175 - L177. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lajoie, E. A. Partridge, G. Guay, J. G. Goetz, J. Pawling, A. Lagana, B. Joshi, J. W. Dennis, and I. R. Nabi Plasma membrane domain organization regulates EGFR signaling in tumor cells J. Cell Biol., October 22, 2007; 179(2): 341 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-q. Wang, Q. Yan, P. Sun, J.-W. Liu, L. Go, S. M. McDaniel, and A. S. Paller Suppression of Epidermal Growth Factor Receptor Signaling by Protein Kinase C-{alpha} Activation Requires CD82, Caveolin-1, and Ganglioside Cancer Res., October 15, 2007; 67(20): 9986 - 9995. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Nixon, A. Carter, J. Wegner, C. Ferguson, M. Floetenmeyer, J. Riches, B. Key, M. Westerfield, and R. G. Parton Caveolin-1 is required for lateral line neuromast and notochord development J. Cell Sci., July 1, 2007; 120(13): 2151 - 2161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Costa, M. Senou, F. Van Rode, J. Ruf, M. Capello, D. Dequanter, P. Lothaire, C. Dessy, J. E. Dumont, M.-C. Many, et al. Reciprocal Negative Regulation between Thyrotropin/3',5'-Cyclic Adenosine Monophosphate-Mediated Proliferation and Caveolin-1 Expression in Human and Murine Thyrocytes Mol. Endocrinol., April 1, 2007; 21(4): 921 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Sotgia, H. Rui, G. Bonuccelli, I. Mercier, R. G. Pestell, and M. P. Lisanti Caveolin-1, Mammary Stem Cells, and Estrogen-Dependent Breast Cancers. Cancer Res., November 15, 2006; 66(22): 10647 - 10651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Li, F. Sotgia, M. A. Vuolo, M. Li, W. C. Yang, R. G. Pestell, J. A. Sparano, and M. P. Lisanti Caveolin-1 Mutations in Human Breast Cancer: Functional Association with Estrogen Receptor {alpha}-Positive Status Am. J. Pathol., June 1, 2006; 168(6): 1998 - 2013. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Hassan, T. M. Williams, P. G. Frank, and M. P. Lisanti Caveolin-1-deficient aortic smooth muscle cells show cell autonomous abnormalities in proliferation, migration, and endothelin-based signal transduction Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2393 - H2401. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. A. Torres, J. C. Tapia, D. A. Rodriguez, M. Parraga, P. Lisboa, M. Montoya, L. Leyton, and A. F. G. Quest Caveolin-1 controls cell proliferation and cell death by suppressing expression of the inhibitor of apoptosis protein survivin J. Cell Sci., May 1, 2006; 119(9): 1812 - 1823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Schwencke, R. C. Braun-Dullaeus, C. Wunderlich, and R. H. Strasser Caveolae and caveolin in transmembrane signaling: Implications for human disease Cardiovasc Res, April 1, 2006; 70(1): 42 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Miotti, A. Tomassetti, I. Facetti, E. Sanna, V. Berno, and S. Canevari Simultaneous Expression of Caveolin-1 and E-Cadherin in Ovarian Carcinoma Cells Stabilizes Adherens Junctions through Inhibition of src-Related Kinases Am. J. Pathol., November 1, 2005; 167(5): 1411 - 1427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Zorn, T. Bonome, L. Gangi, G. V.R. Chandramouli, C. S. Awtrey, G. J. Gardner, J. C. Barrett, J. Boyd, and M. J. Birrer Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer Clin. Cancer Res., September 15, 2005; 11(18): 6422 - 6430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Williams, G. S. Hassan, J. Li, A. W. Cohen, F. Medina, P. G. Frank, R. G. Pestell, D. Di Vizio, M. Loda, and M. P. Lisanti Caveolin-1 Promotes Tumor Progression in an Autochthonous Mouse Model of Prostate Cancer: GENETIC ABLATION OF Cav-1 DELAYS ADVANCED PROSTATE TUMOR DEVELOPMENT IN TRAMP MICE J. Biol. Chem., July 1, 2005; 280(26): 25134 - 25145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Bonuccelli, F. Sotgia, P. G. Frank, T. M. Williams, C. J. de Almeida, H. B. Tanowitz, P. E. Scherer, K. A. Hotchkiss, B. I. Terman, B. Rollman, et al. ATR/TEM8 is highly expressed in epithelial cells lining Bacillus anthracis' three sites of entry: implications for the pathogenesis of anthrax infection Am J Physiol Cell Physiol, June 1, 2005; 288(6): C1402 - C1410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Williams and M. P. Lisanti Caveolin-1 in oncogenic transformation, cancer, and metastasis Am J Physiol Cell Physiol, March 1, 2005; 288(3): C494 - C506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Cohen, R. Hnasko, W. Schubert, and M. P. Lisanti Role of Caveolae and Caveolins in Health and Disease Physiol Rev, October 1, 2004; 84(4): 1341 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hnasko and M. P. Lisanti The Biology of Caveolae: Lessons from Caveolin Knockout Mice and Implications for Human Disease Mol. Interv., December 1, 2003; 3(8): 445 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Woodman, A. W. Ashton, W. Schubert, H. Lee, T. M. Williams, F. A. Medina, J. B. Wyckoff, T. P. Combs, and M. P. Lisanti Caveolin-1 Knockout Mice Show an Impaired Angiogenic Response to Exogenous Stimuli Am. J. Pathol., June 1, 2003; 162(6): 2059 - 2068. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
